1887

Journal of Medical Microbiology logo

Volume 72, Issue 6

Changes in serum amyloid A, plasma high-density lipoprotein cholesterol and apolipoprotein A-I as useful biomarkers for infection No Access

Abstract

In recent years, cholesterol has received interest in the study of infection due to evidence of a relationship between low plasma cholesterol levels and tuberculosis (TB).

Plasma lipid profiles of serum amyloid A (SAA), apolipoprotein A-I and high-density lipoprotein cholesterol (HDL-C) are biomarkers associated with symptomatic TB patients.

We aimed to evaluate plasma lipid profiles of apolipoprotein A-I, SAA and the size of HDL as biomarkers to diagnose symptomatic TB patients.

Patients with TB symptoms attending the Instituto Brasileiro para a Investigação da Tuberculose/Fundação José Silveira (IBIT/FJS) between September 2015 and August 2016 for diagnosis of TB were studied. From 129 patients, 97 were classified as pulmonary TB and 32 as negative-bacilloscopy (non-TB group). Medical history, fasting serum and plasma were obtained. Total cholesterol (TC), HDL-C, apolipoprotein A-I and SAA were measured by enzymatic or immunochemical reaction assays. HDL size was measured by laser light-scattering.

In TB patients, TC (147.0±37 vs. 168±44 mg dL), HDL-C (37±14 vs. 55±18 mg dL) and apolipoprotein A-I (102±41 vs. 156±47 mg dL) concentrations were lower (<0.0001), while HDL particle size (10.16±1.02 vs. 9.62±0.67 nm) and SAA levels (280±36 vs. 19±8 mg L) were higher (<0.0001). Using receiver-operating characteristic curve analysis for predicting TB, the cutoff values were <83.85 mg L for SAA (sensitivity=96.88 %, specificity=78.43 %, <0.0001), >44.50 mg dL for HDL-C (sensitivity=75 %, specificity=72.16 %, <0.001) and >118.5 mg dL for apolipoprotein A-I (sensitivity=83.83 %, specificity=72.22 %, <0.001).

SAA, HDL-C and apolipoprotein A-I are associated with TB infection and could be used as laboratory biomarkers, especially in patients who are negative for alcohol-acid-resistant bacilli.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): apolipoprotein A-I , HDL-C , lipoprotein diameter , serum amyloid A and tuberculosis-associated biomarkers
Funding
This study was supported by the:
  • Fundação de Amparo à Pesquisa do Estado da Bahia (Award Scholarship_Fapesb)
    • Principle Award Recipient: Adrianode Souza Santos Monteiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
    • Principle Award Recipient: RaulCavalcante Maranhão
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Award CAPES – Finance Code 001)
    • Principle Award Recipient: NadielleSilva Bidu
  • Fundação de Amparo à Pesquisa do Estado da Bahia (Award PPSUS_2010)
    • Principle Award Recipient: RicardoDavid Couto
© 2023 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001726
2023-06-30
2024-05-02
Loading full text...

Full text loading...

References

  1. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–550 [View Article] [PubMed]
     [Google Scholar]
  2. Global tuberculosis report Geneva: World Health Organization; 2019
  3. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29:565–578 [PubMed]
     [Google Scholar]
  4. Rossetti MLR, Valim A de M, Silva MSN, Rodrigues VS. Tuberculose Resistente: Revisão molecular resistant tuberculosis: a molecular review. Rev Saúde Pública 2002; 36:525–532 [View Article]
     [Google Scholar]
  5. Cayci YT, Bilgin K, Coban AY, Birinci A, Durupınar B. An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF. Mem Inst Oswaldo Cruz 2017; 112:756–759 [View Article] [PubMed]
     [Google Scholar]
  6. Shu C-C, Wang J-Y, Yu C-J, Lee L-N, Luh K-T. Improving tuberculosis diagnostics with biomarkers. Curr Biomark Find 2015; 5:13 [View Article]
     [Google Scholar]
  7. Akpovi DC, Gbaguidi LHS, Anago E nie, Affolabi D, Dougnon T gnon V et al. Tuberculosis treatment raises total cholesterol level and restores high density lipoprotein cholesterol (HDL-C) in patients with pulmonary tuberculosis. Afr J Biotechnol 2013; 12:6019–6024 [View Article]
     [Google Scholar]
  8. Oyedeji SO, Oguntuase NR, Esan A, Adesina AA, Oke OT et al. Oxidative Stress and Lipid Profile Status in Pulmonary Tuberculosis Patients in South Western Nigeria. Greener J Med Sci 2013; 3:228–232 [View Article]
     [Google Scholar]
  9. Yamanaka K, Sakai S, Nomura F, Akashi T, Usui T. A nutritional investigation of homeless patients with tuberculosis. Kekkaku 2001; 76:363–370 [PubMed]
     [Google Scholar]
  10. Gebremicael G, Amare Y, Challa F, Gebreegziabxier A, Medhin G et al. Lipid Profile in Tuberculosis Patients with and without Human Immunodeficiency Virus Infection. Int J Chronic Dis 2017; 2017:1–7 [View Article] [PubMed]
     [Google Scholar]
  11. Deniz O, Gumus S, Yaman H, Ciftci F, Ors F et al. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem 2007; 40:162–166 [View Article] [PubMed]
     [Google Scholar]
  12. Sasaki Y, Yamagishi F, Yagi T, Mizutani F. A case of pulmonary tuberculosis case with pancytopenia accompanied to bone marrow gelatinous transformation. Kekkaku 1999; 74:361–364 [PubMed]
     [Google Scholar]
  13. Santos APC, Vieira MS, Deus DF, de Oliveira RJB, Morikawa AT et al. Atherogenic Indices and HDL Particle Size as Laboratory Parameters to Evaluate Cardiovascular Risk in the Presence of Dyslipidemia. J Biophys Chem 2014; 05:24–32 [View Article]
     [Google Scholar]
  14. Levels JHM, Marquart JA, Abraham PR, van den Ende AE, Molhuizen HOF et al. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun 2005; 73:2321–2326 [View Article] [PubMed]
     [Google Scholar]
  15. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155:269–281 [View Article] [PubMed]
     [Google Scholar]
  16. Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M et al. Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in A Randomized Clinical Trial. EBioMedicine 2017; 25:112–121 [View Article] [PubMed]
     [Google Scholar]
  17. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26:427–435 [View Article] [PubMed]
     [Google Scholar]
  18. Brasil Manual Nacional de Vigilância Laboratorial Da Tuberculose e Outras Micobactérias Brasília: Ministério da Saúde; 2008
     [Google Scholar]
  19. Brasil Manual de Recomendações Para o Controle Da Tuberculose No Brasil Brasília: Ministério da Saúde; 2019
     [Google Scholar]
  20. Abe C, Hirano K, Tomiyama T. Simple and rapid identification of the Mycobacterium tuberculosis complex by immunochromatographic assay using anti-MPB64 monoclonal antibodies. J Clin Microbiol 1999; 37:3693–3697 [View Article] [PubMed]
     [Google Scholar]
  21. Lima ES, Maranhão RC. Rapid, simple laser-light-scattering method for HDL particle sizing in whole plasma. Clin Chem 2004; 50:1086–1088 [View Article] [PubMed]
     [Google Scholar]
  22. Berrar D, Flach P. Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them). Brief Bioinform 2012; 13:83–97 [View Article] [PubMed]
     [Google Scholar]
  23. Babu S. Biomarkers for Treatment Monitoring in Tuberculosis: A New Hope. EBioMedicine 2017; 26:13–14 [View Article] [PubMed]
     [Google Scholar]
  24. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R et al. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 2016; 16:e34–46 [View Article] [PubMed]
     [Google Scholar]
  25. Correia-Neves M, Fröberg G, Korshun L, Viegas S, Vaz P et al. Biomarkers for tuberculosis: the case for lipoarabinomannan. ERJ Open Res 2019; 5:00115-2018 [View Article] [PubMed]
     [Google Scholar]
  26. Pérez-Guzmán C, Vargas MH, Quiñonez F, Bazavilvazo N, Aguilar A. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 2005; 127:643–651 [View Article] [PubMed]
     [Google Scholar]
  27. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000; 20:763–772 [View Article] [PubMed]
     [Google Scholar]
  28. Pepys MB. Acute phase proteins. In Encyclopedia of Immunology vol 1998 pp 18–20 [View Article]
     [Google Scholar]
  29. Kanna KS. Effect of the lipid profile differs with tuberculosis subject innovation to eliminate-a review. Asia Pacific J Res 2015; 1:185–190
     [Google Scholar]
  30. Sushilendu DV. Study of Lipid profile in pulmonary TB cases: pre and post anti-tuberculosis treatment. J Med Sci Clin Res 2019; 7:211–215 [View Article]
     [Google Scholar]
  31. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283–298 [View Article] [PubMed]
     [Google Scholar]
  32. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens P et al. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax 2016; 71:785–794 [View Article] [PubMed]
     [Google Scholar]
  33. Jacobs R, Malherbe S, Loxton AG, Stanley K, van der Spuy G et al. Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. Oncotarget 2016; 7:57581–57592 [View Article] [PubMed]
     [Google Scholar]
  34. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. The next generation of molecular tests will challenge existing TB infrastructure in high burden countries. Eur Respir J 2013; 42:544–547 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001726
Loading
Changes in serum amyloid A, plasma high-density lipoprotein cholesterol and apolipoprotein A-I as useful biomarkers for Mycobacterium tuberculosis infection
J. Med. Microbiol. 72, 001726 (2023); https://doi.org/10.1099/jmm.0.001726
/content/journal/jmm/10.1099/jmm.0.001726
/content/journal/jmm/10.1099/jmm.0.001726
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error